JPMorgan creates healthcare venture capital team

JPMorgan has launched a healthcare venture capital team targeting the life sciences. 

The team, Life Sciences Private Capital, plans to invest in early- to later-stage healthcare companies and seeks to capitalize on innovation in areas such as genetic medicine, autoimmune diseases, cardiometabolic diseases and rare disorders, according to a Nov. 1 press release from JPMorgan. 

A group of advisers will assist the investment team, meeting regularly and providing guidance as needed to help portfolio companies. The advisers are:

  • Laurie Glimcher, MD, president and CEO of the Boston-based Dana-Farber Cancer Institute

  • Jeffrey Leiden, MD, PhD, executive chair and former CEO of drug developer Vertex Pharmaceuticals

  • Frederic Moll, MD, a robotic surgery pioneer and entrepreneur who is now an executive at Johnson & Johnson

  • Stephen Oesterle, MD, former senior vice president for medicine and technology at medical-technology company Medtronic

  • Robert Stockman, co-founder and former CEO of medical device company REVA Medical

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like